Trial Profile

A Phase IIa Proof of Concept Study to Explore the Efficacy, Tolerability and Safety of Fosmidomycin Sodium When Administered With Piperaquine Tetraphosphate to Adults and Older Children With Acute Uncomplicated Plasmodium Falciparum Malaria

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Jan 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fosmidomycin (Primary) ; Fosmidomycin+piperaquine (Primary) ; Piperaquine (Primary)
Indications Falciparum malaria
Focus Proof of concept; Therapeutic Use
Acronyms FOSPIP
Sponsors Jomaa Pharma

26 Dec 2017 Primary endpoint (Per protocol, PCR-corrected cure rate on Day 28) has been met as per the results published in the Clinical Infectious Diseases
26 Dec 2017 Results assessing safety and efficacy published in the Clinical Infectious Diseases
14 Nov 2016 According to Jomaa Pharma media release, scientific paper on this study was presented at the 65th Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com